Evidence map›Paper›PMID 41077616›Full record

SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Evaluating the neuroprotective effect of GLP-1 receptor agonists in parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.

Yago Marcos Pessoa-Gonçalves, Victor Hugo Palhares Flávio-Reis, Chamberttan Souza Desidério, Marlos Aureliano Dias-Sousa, Carlo José Freire Oliveira, Rubens Gisbert Cury, Wellington Francisco Rodrigues

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yago Marcos Pessoa-Gonçalves *Immunology Laboratory and Bioinformatics, Institute of Natural and Biological Sciences, Universidade Federal do Triângulo Mineiro, 100 Vigário Carlo Street, Uberaba, 38025-180, MG, Brazil.
Victor Hugo Palhares Flávio-Reis *Immunology Laboratory and Bioinformatics, Institute of Natural and Biological Sciences, Universidade Federal do Triângulo Mineiro, 100 Vigário Carlo Street, Uberaba, 38025-180, MG, Brazil.
Chamberttan Souza DesidérioImmunology Laboratory and Bioinformatics, Institute of Natural and Biological Sciences, Universidade Federal do Triângulo Mineiro, 100 Vigário Carlo Street, Uberaba, 38025-180, MG, Brazil.
Marlos Aureliano Dias-SousaImmunology Laboratory and Bioinformatics, Institute of Natural and Biological Sciences, Universidade Federal do Triângulo Mineiro, 100 Vigário Carlo Street, Uberaba, 38025-180, MG, Brazil.
Carlo José Freire OliveiraImmunology Laboratory and Bioinformatics, Institute of Natural and Biological Sciences, Universidade Federal do Triângulo Mineiro, 100 Vigário Carlo Street, Uberaba, 38025-180, MG, Brazil. carlo.oliveira@uftm.edu.br.ORCID http://orcid.org/0000-0003-2211-7333
Rubens Gisbert CuryDepartment of Neurology, Center for Movement Disorders, Universidade de São Paulo, 255 Dr. Enéas de Carvalho Aguiar Avenue, São Paulo, 05402-000, SP, Brazil. rubens.cury@hc.fm.usp.br.
Wellington Francisco RodriguesImmunology Laboratory and Bioinformatics, Institute of Natural and Biological Sciences, Universidade Federal do Triângulo Mineiro, 100 Vigário Carlo Street, Uberaba, 38025-180, MG, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnimal studies have shown that Glucagon-like Peptide 1 (GLP-1) exerts neuroprotective effects on dopaminergic neurons in the substantia nigra and promotes functional recovery in animals. These preclinical findings suggest that GLP-1 receptor agonist drugs could be promising for treating Parkinson’s disease (PD). This exploratory meta-analysis investigated the efficacy of GLP-1 agonists in the treatment of PD in randomized clinical trials.

methodsA systematic literature search was conducted to evaluate the neuroprotective effects of GLP-1 receptor agonists in patients with PD, including all relevant articles published up to July 2, 2025. Data extraction focused on mean differences (MD) and standard deviations of the placebo or intervention groups compared with the baseline states. The effect sizes were calculated using the inverse variance statistical method.

resultsA meta-analysis of six studies, including 428 patients with PD and 329 controls, revealed no statistically significant overall improvement across all sections of the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). Additionally, no significant changes were observed in the Levodopa Equivalent Daily Dose (LED), the Mattis Dementia Rating Scale–Second Edition (MATTIS-DRS2), or the Parkinson’s Disease Questionnaire (PDQ-39).

conclusionsGLP-1 agonists did not demonstrate a neuroprotective effect compared to placebo. Future clinical trials with larger sample sizes, extended durations, and targeted focus on specific patient subgroups and disease stages are warranted to more accurately assess the long-term efficacy of GLP-1 in PD.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsNeuroprotective AgentsParkinson DiseaseRandomized Controlled Trials as TopicHumansGlucagon-Like Peptide-1 Receptor AgonistsNeuroprotective AgentsGLP-1Meta-analysisParkinson diseaseRandomized controlled trialSystematic review

Identifiers

PMID41077616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.